Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern

Diseases of the Esophagus

Volumn 28, Issue 5, 2015, Pages 453-459

  Versteijne, Eva ^a   van Laarhoven, H W M ^a   van Hooft, J E ^a   van Os, R M ^a   Geijsen, E D ^a   van Berge Henegouwen, M I ^a   Hulshof, M C C M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

definitive chemoradiation; esophageal cancer; locoregional recurrence

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DEFINITIVE CHEMORADIATION; ESOPHAGUS CANCER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LOCAL METASTASIS; LOCAL RECURRENCE FREE SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION FIELD; RETROSPECTIVE STUDY; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; LYMPH NODE; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899042086     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12215     Document Type: Article

References (21)

1. Ferlay J, Shin H R, Bray F, Forman D, Mathers C, Parkin D M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917.
2. Dikken J L, Lemmens V E, Wouters M W et al. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer 2012; 48: 1624–1632.
3. van Hagen P, Hulshof M C C M, van Lanschot J J B et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074–2084.
4. Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T. Definitive chemoradiation for oesophageal cancer – a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol) 2011; 23: 182–188.
5. Teoh A Y, Chiu P W, Yeung W K, Liu S Y W, Wong S K H, Ng E K W. Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol 2013; 24: 165–171.
6. Tougeron D, Di Fiore F, Hamidou H et al. Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis. Oncology 2007; 73: 328–334.
7. Welsh J, Settle S H, Amini A et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012; 118: 2632–2640.
8. Button M R, Morgan C A, Croydon E S, Roberts S A, Crosby T D. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 73: 818–823.
9. Denham J W, Steigler A, Kilmurray J et al. Relapse patterns after chemo-radiation for carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 2003; 15: 98–108.
10. Reid T D, Davies I L, Mason J, Roberst S A, Crosby T D, Lewis W G. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma. Clin Oncol (R Coll Radiol) 2012; 24: 617–624.
11. Ishihara R, Yamamoto S, Iishi H et al. Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010; 76: 123–129.
12. Courrech Staal E F, Aleman B M, van Velthuysen M L et al. Chemoradiation for esophageal cancer: institutional experience with three different regimens. Am J Clin Oncol 2011; 34: 343–349.
13. Ruppert B N, Watkins J M, Shirai K et al. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol 2010; 33: 346–352.
14. Wang H, Ryu J, Gandara D et al. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol 2007; 2: 153–157.
15. Minsky B D, Pajak T F, Ginsberg R J et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167–1174.
16. SudoK, XiaoL, WadhwaRet al. Pattern of local-regional relapse and survival after bimodality therapy for esophageal cancer: Implications for the surveillance strategy. ASCO Annual meeting, General Poster Session.
17. Onozawa M, Nihei K, Ishikura S et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 2009; 92: 266–269.
18. Welsh J, Palmer M B, Ajani J A et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 2012; 82: 468–474.
19. Lin S H, Wang L, Myles B et al. Propensity score-BASED comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 84: 1078–1085.
20. Amini A, Xiao L, Allen P K et al. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys 2012; 83: e231–239.
21. Burmeister B H, Smithers B M, Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6: 659–668.